WuXi AppTec's stock plummeted 5.05% during intraday trading on Friday, continuing a pattern of significant declines for the pharmaceutical company.
The sharp drop follows sustained selling pressure triggered by a document recently submitted by US lawmakers, which has weighed heavily on WuXi-affiliated stocks. Despite the company disclosing positive signals about its business portfolio and expected contributions from new orders, short-term market sentiment remains dominated by these external headwinds, leading to evident capital outflow pressure and consecutive sessions of declines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments